BR
Brii Biosciences Limited
BRIBF · OTC
$0.13 +0.00% (+$0.00)
Market Cap ¥628.2M
P/E Ratio -
Div. Yield -
ROE 8.91%
Bulios Fair Price
$0.08
38.5% downside
Current Price
$0.13
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BRIBF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
50 /100
Fair P/S 34.66x
P/B 0.26x
P/E N/A
Growth
0 /100
Declining Rev. growth 29.45%
Book val. growth 9.39%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 0.00%
Net margin 1,196.58%
Op. margin 1,632.59%
Quality
0 /100
Poor ROIC 12.79%
ROE 8.91%
ROA 9.19%
Debt
69 /100
Low Debt/Equity 0.00x
Current ratio 60.73x
Int. coverage -154.89x
Stability
16 /100
Unstable Beta 1.20x
Rev. volatility 4,661.91%
EPS volatility 145.72%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BRIBF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Zhi Hong
Employees
75
Headquarters
Beijing
Upcoming events
19 MAR
Earnings
Upcoming earnings report